Immune checkpoint inhibitors vs any second‐line chemotherapy: Time to progression
It is very uncertain whether immune checkpoint inhibitors changes time to disease progression Range of compared with any second‐line chemotherapy (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Immune checkpoint inhibitors vs any second‐line chemotherapy Time to disease progression Range of · participants with advanced or metastatic muscle invasive bladder cancer It is very uncertain whether immune checkpoint inhibitors changes time to disease progression Range of compared with any second‐line chemotherapy (very low certainty). Immunotherapy for advanced or metastatic urothelial carcinoma (2023) · Cochrane Headline outcomes only | HR 0.99 [0.84, 1.16] | 2 studies · 1473 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.